124 STAT. 964 PUBLIC LAW 111–148—MAR. 23, 2010 (c) ELIMINATION OF MA REGIONAL PLAN STABILIZATION FUND.— (1) IN GENERAL.—Section 1858 of the Social Security Act (42 U.S.C. 1395w–27a) is amended by striking subsection (e). (2) TRANSITION.—Any amount contained in the MA Regional Plan Stabilization Fund as of the date of the enact- ment of this Act shall be transferred to the Federal Supple- mentary Medical Insurance Trust Fund. SEC. 10328. IMPROVEMENT IN PART D MEDICATION THERAPY MANAGE- MENT (MTM) PROGRAMS. (a) IN GENERAL.—Section 1860D–4(c)(2) of the Social Security Act (42 U.S.C. 1395w–104(c)(2)) is amended— (1) by redesignating subparagraphs (C), (D), and (E) as subparagraphs (E), (F), and (G), respectively; and (2) by inserting after subparagraph (B) the following new subparagraphs: ‘‘(C) REQUIRED INTERVENTIONS.—For plan years begin- ning on or after the date that is 2 years after the date of the enactment of the Patient Protection and Affordable Care Act, prescription drug plan sponsors shall offer medi- cation therapy management services to targeted bene- ficiaries described in subparagraph (A)(ii) that include, at a minimum, the following to increase adherence to prescrip- tion medications or other goals deemed necessary by the Secretary: ‘‘(i) An annual comprehensive medication review furnished person-to-person or using telehealth tech- nologies (as defined by the Secretary) by a licensed pharmacist or other qualified provider. The comprehen- sive medication review— ‘‘(I) shall include a review of the individual’s medications and may result in the creation of a recommended medication action plan or other actions in consultation with the individual and with input from the prescriber to the extent nec- essary and practicable; and ‘‘(II) shall include providing the individual with a written or printed summary of the results of the review. The Secretary, in consultation with relevant stake- holders, shall develop a standardized format for the action plan under subclause (I) and the summary under subclause (II). ‘‘(ii) Follow-up interventions as warranted based on the findings of the annual medication review or the targeted medication enrollment and which may be provided person-to-person or using telehealth tech- nologies (as defined by the Secretary). ‘‘(D) ASSESSMENT.—The prescription drug plan sponsor shall have in place a process to assess, at least on a quarterly basis, the medication use of individuals who are at risk but not enrolled in the medication therapy manage- ment program, including individuals who have experienced a transition in care, if the prescription drug plan sponsor has access to that information. 42 USC 1395w–27a note.
